Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice

Q. G. De Lussanet; R. G.H. Beets-Tan; W. H. Backes; D. W.J. Van Der Schaft; J. M.A. Van Engelshoven; K. H. Mayo; A. W. Griffioen

doi:10.1016/j.ejca.2004.01.020

Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice

Q. G. De Lussanet, R. G.H. Beets-Tan, W. H. Backes, D. W.J. Van Der Schaft, J. M.A. Van Engelshoven, K. H. Mayo, A. W. Griffioen

Chemical and Structural Biology (TMED)

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

The purpose of this study was to evaluate the effects of anginex on tumour angiogenesis assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. C57BL/6 mice carrying B16F10 melanomas were treated with anginex, TNP-470 or saline. Tumour growth curves and microvessel density (MVD) were recorded to establish the effects of treatment. DCE-MRI was performed on day 16 after tumour inoculation, and the endothelial transfer coefficients of the microvessel permeability surface-area product (K^PS) were calculated using a two-compartment model. Both anginex and TNP-470 resulted in smaller tumour volumes (P<0.0001) and lower MVD (P <0.05) compared to saline. Treatment with anginex resulted in a 64% reduction (P<0.01) of tumour K^PS and TNP-470 resulted in a 44% reduction (P=0.17), compared to saline. DCE-MRI with a clinically available, small-molecular contrast agent can therefore be used to evaluate the angiostatic effects of anginex and TNP-470 on tumour angiogenesis.

Original language	English (US)
Pages (from-to)	1262-1268
Number of pages	7
Journal	European Journal of Cancer
Volume	40
Issue number	8
DOIs	https://doi.org/10.1016/j.ejca.2004.01.020
State	Published - May 2004

Bibliographical note

Funding Information:
This work was supported by research grants from the National Institutes of Health (CA-96090), the U.S. Department of Defence (Army) (DA/DAMD17-99-1-9564), the Dutch Cancer Society (UM 2001-2529) and ActiPep Biotechnology, Inc. We are grateful to Denisha Walek of the Microchemical Facility of the University of Minnesota, for expertise in the synthesis of peptides.

Keywords

Anginex
Angiogenesis inhibitors
Angiostatic agents
B16 melanoma
Gadopentetate dimeglumine
Gd-DTPA
MRI
MRI, functional
Mice
Microvascular permeability
TNP-470

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.ejca.2004.01.020

OpenUrl availability

Full text

Cite this

De Lussanet, Q. G., Beets-Tan, R. G. H., Backes, W. H., Van Der Schaft, D. W. J., Van Engelshoven, J. M. A., Mayo, K. H., & Griffioen, A. W. (2004). Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. European Journal of Cancer, 40(8), 1262-1268. https://doi.org/10.1016/j.ejca.2004.01.020

De Lussanet, QG, Beets-Tan, RGH, Backes, WH, Van Der Schaft, DWJ, Van Engelshoven, JMA, Mayo, KH & Griffioen, AW 2004, 'Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice', European Journal of Cancer, vol. 40, no. 8, pp. 1262-1268. https://doi.org/10.1016/j.ejca.2004.01.020

@article{746ac3527ff1476badf8203536b4107e,

title = "Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice",

abstract = "The purpose of this study was to evaluate the effects of anginex on tumour angiogenesis assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. C57BL/6 mice carrying B16F10 melanomas were treated with anginex, TNP-470 or saline. Tumour growth curves and microvessel density (MVD) were recorded to establish the effects of treatment. DCE-MRI was performed on day 16 after tumour inoculation, and the endothelial transfer coefficients of the microvessel permeability surface-area product (KPS) were calculated using a two-compartment model. Both anginex and TNP-470 resulted in smaller tumour volumes (P<0.0001) and lower MVD (P <0.05) compared to saline. Treatment with anginex resulted in a 64% reduction (P<0.01) of tumour KPS and TNP-470 resulted in a 44% reduction (P=0.17), compared to saline. DCE-MRI with a clinically available, small-molecular contrast agent can therefore be used to evaluate the angiostatic effects of anginex and TNP-470 on tumour angiogenesis.",

keywords = "Anginex, Angiogenesis inhibitors, Angiostatic agents, B16 melanoma, Gadopentetate dimeglumine, Gd-DTPA, MRI, MRI, functional, Mice, Microvascular permeability, TNP-470",

author = "{De Lussanet}, {Q. G.} and Beets-Tan, {R. G.H.} and Backes, {W. H.} and {Van Der Schaft}, {D. W.J.} and {Van Engelshoven}, {J. M.A.} and Mayo, {K. H.} and Griffioen, {A. W.}",

note = "Funding Information: This work was supported by research grants from the National Institutes of Health (CA-96090), the U.S. Department of Defence (Army) (DA/DAMD17-99-1-9564), the Dutch Cancer Society (UM 2001-2529) and ActiPep Biotechnology, Inc. We are grateful to Denisha Walek of the Microchemical Facility of the University of Minnesota, for expertise in the synthesis of peptides.",

year = "2004",

month = may,

doi = "10.1016/j.ejca.2004.01.020",

language = "English (US)",

volume = "40",

pages = "1262--1268",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice

AU - De Lussanet, Q. G.

AU - Beets-Tan, R. G.H.

AU - Backes, W. H.

AU - Van Der Schaft, D. W.J.

AU - Van Engelshoven, J. M.A.

AU - Mayo, K. H.

AU - Griffioen, A. W.

N1 - Funding Information: This work was supported by research grants from the National Institutes of Health (CA-96090), the U.S. Department of Defence (Army) (DA/DAMD17-99-1-9564), the Dutch Cancer Society (UM 2001-2529) and ActiPep Biotechnology, Inc. We are grateful to Denisha Walek of the Microchemical Facility of the University of Minnesota, for expertise in the synthesis of peptides.

PY - 2004/5

Y1 - 2004/5

N2 - The purpose of this study was to evaluate the effects of anginex on tumour angiogenesis assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. C57BL/6 mice carrying B16F10 melanomas were treated with anginex, TNP-470 or saline. Tumour growth curves and microvessel density (MVD) were recorded to establish the effects of treatment. DCE-MRI was performed on day 16 after tumour inoculation, and the endothelial transfer coefficients of the microvessel permeability surface-area product (KPS) were calculated using a two-compartment model. Both anginex and TNP-470 resulted in smaller tumour volumes (P<0.0001) and lower MVD (P <0.05) compared to saline. Treatment with anginex resulted in a 64% reduction (P<0.01) of tumour KPS and TNP-470 resulted in a 44% reduction (P=0.17), compared to saline. DCE-MRI with a clinically available, small-molecular contrast agent can therefore be used to evaluate the angiostatic effects of anginex and TNP-470 on tumour angiogenesis.

AB - The purpose of this study was to evaluate the effects of anginex on tumour angiogenesis assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. C57BL/6 mice carrying B16F10 melanomas were treated with anginex, TNP-470 or saline. Tumour growth curves and microvessel density (MVD) were recorded to establish the effects of treatment. DCE-MRI was performed on day 16 after tumour inoculation, and the endothelial transfer coefficients of the microvessel permeability surface-area product (KPS) were calculated using a two-compartment model. Both anginex and TNP-470 resulted in smaller tumour volumes (P<0.0001) and lower MVD (P <0.05) compared to saline. Treatment with anginex resulted in a 64% reduction (P<0.01) of tumour KPS and TNP-470 resulted in a 44% reduction (P=0.17), compared to saline. DCE-MRI with a clinically available, small-molecular contrast agent can therefore be used to evaluate the angiostatic effects of anginex and TNP-470 on tumour angiogenesis.

KW - Anginex

KW - Angiogenesis inhibitors

KW - Angiostatic agents

KW - B16 melanoma

KW - Gadopentetate dimeglumine

KW - Gd-DTPA

KW - MRI

KW - MRI, functional

KW - Mice

KW - Microvascular permeability

KW - TNP-470

UR - http://www.scopus.com/inward/record.url?scp=1942520181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942520181&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2004.01.020

DO - 10.1016/j.ejca.2004.01.020

M3 - Article

C2 - 15110892

AN - SCOPUS:1942520181

SN - 0959-8049

VL - 40

SP - 1262

EP - 1268

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 8

ER -

Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this